Today on the Daily Dive, Fabio Chianelli, CEO of PharmaTher Inc (CSE: PHRM) sits down with our host Cassandra Leah to discuss the company as well as the psychedelic space in general. Within, he discusses his outlook for the growing psychedelic renaissance as well as the direction that PharmaTher is headed in terms of research and development.
Pharmather is one of the latest firms to begin trading on the Canadian Securities Exchange, with a focus on the psychedelic space. The company works to combine artificial intelligence with research and development to develop solutions for unmet medical needs with these psychedelic compounds. The company is currently focused on the brain and nervous system, with a number of target conditions already identified.
Check out the full interview below.
FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.